Redsense Medical (REDS) Q2 2025 earnings summary

Executive summary

• Net sales for Q2 2025 were KSEK 6,276, a 28% decrease year-over-year, with the US accounting for 99% of sales.

• Operating loss (EBIT) for Q2 was KSEK -1,833, compared to a profit of KSEK 613 in Q2 2024.

• Result after tax for Q2 was KSEK -1,830, with EPS at SEK -1.11.

• Cash and cash equivalents as of June 30, 2025, were KSEK 14,692.

• Gross margin for Q2 was 58%.

Financial highlights

• Net sales for H1 2025 were KSEK 11,052, up 6% year-over-year.

• Gross profit for Q2 was KSEK 3,624, down from KSEK 5,419 in Q2 2024.

• Operating loss for H1 2025 was KSEK -4,986, compared to KSEK -2,043 in H1 2024.

• Cash flow from operating activities for H1 2025 was KSEK -32.

• Solidity at the end of Q2 was 90%.

Outlook and guidance

• Sales for H1 2025 were higher than the same period last year, with secured growth for Q3 due to preemptive orders.

• The company is positioned for sustainable growth with strengthened internal capabilities and expanded leadership.

• Ongoing efforts to secure a dedicated HCPCS code in the US are expected to support future reimbursement.